OncoMatch/Clinical Trials/NCT07393542
A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma
Is NCT07393542 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including SHR-A2102 and Adebrelimab and Gemcitabine and cisplatin / carboplatin for locally advanced or metastatic urothelial carcinoma.
Treatment: SHR-A2102 and Adebrelimab · Gemcitabine and cisplatin / carboplatin — The study is being conducted to evaluate the efficacy of SHR-A2102 with adebrelimab versus gemcitabine in combination with cisplatin/carboplatin in previously untreated locally advanced or metastatic urothelial carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Urothelial Carcinoma
Biomarker criteria
Required: NECTIN4 expression testing required (testing required; no eligibility threshold specified)
Able to provide archived or fresh tumor tissue for Nectin-4 and PD-L1 expression.
Required: PD-L1 (CD274) expression testing required (testing required; no eligibility threshold specified)
Able to provide archived or fresh tumor tissue for Nectin-4 and PD-L1 expression.
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: antibody-drug conjugate targeting NECTIN4
Previously received therapy with an antibody-drug conjugate that meets any one of the following characteristics: targeting Nectin-4
Cannot have received: antibody-drug conjugate containing irinotecan or its derivatives and acting as a topoisomerase I inhibitor
Previously received therapy with an antibody-drug conjugate that meets any one of the following characteristics: containing irinotecan or its derivatives and acting as a topoisomerase I inhibitor
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors.
Cannot have received: systemic anti-tumor treatment
Have received systemic anti-tumor treatment within 4 weeks
Cannot have received: anti-tumor Chinese patent medicine
have received prior anti-tumor Chinese patent medicine treatment within 2 weeks
Cannot have received: palliative radiotherapy or local therapy
palliative radiotherapy or local therapy within 2 weeks
Lab requirements
Blood counts
Adequate organ functions.
Kidney function
Adequate organ functions.
Liver function
Adequate organ functions.
Adequate organ functions.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07393542 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require NECTIN4?
Yes, NECTIN4 expression testing required is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 expression testing required is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages